Sandoz prevails over Amgen in Supreme Court case on marketing biosimilars

Trump targets HHS in $810M appropriations clawback

President Donald Trump has moved to cancel $810 million in government spending that has already been appropriated by Congress.

October 02, 2026

By Jacquelyn Cobb

Cancer Policy

Federal judge blocks Trump’s second attempt at imposing $100,000 fee for H1-B visas

Judge Haywood Gilliam, of the U.S. District Court for the Northern District of California, blocked the Trump administration’s second attempt to require a $100,000 fee for H1-B visas, which allows foreign nationals in “specialty occupations” to live and work in the U.S. The fee was previously $5,000 to $10,000.

October 02, 2026

By Sara Willa Ernst

Cancer Policy

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Podcast

The Galleri MCD vote: What FDA asked its advisors to ignore

In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.

September 30, 2026

Podcast The Directors

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science?

September 25, 2026

Vol.52 No.35

By Claire Marie Porter and Paul Goldberg

News Analysis Regulatory News

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says

The FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted in favor of Galleri to become the first multi-cancer detection test to receive regulatory approval.

September 25, 2026

Vol.52 No.35

By Jacquelyn Cobb and Sara Willa Ernst

Sandoz prevails over Amgen in Supreme Court case on marketing biosimilars

YOU MAY BE INTERESTED IN

Trump targets HHS in $810M appropriations clawback

Federal judge blocks Trump’s second attempt at imposing $100,000 fee for H1-B visas

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

The Galleri MCD vote: What FDA asked its advisors to ignore

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says

Renew today!

Subscriber content

Never miss an issue!

Login

Sandoz prevails over Amgen in Supreme Court case on marketing biosimilars

YOU MAY BE INTERESTED IN

Trump targets HHS in $810M appropriations clawback

Federal judge blocks Trump’s second attempt at imposing $100,000 fee for H1-B visas

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

The Galleri MCD vote: What FDA asked its advisors to ignore

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want itLucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claimsClinical benefit will not be considered for approval, FDA says

Never miss an issue!

Login

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says